{"id":140468,"title":"Archived 33: Summary of NACI statement of February 17, 2022: Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-18","captureTimestamp":"2025-04-18T14:14:06.191000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-novavax-nuvaxovid-covid-19-vaccine/summary-february-17-2022.html?wbdisable=true","snippet":"Archived 33: Summary of NACI statement of February 17, 2022: Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine - Canada.ca Skip to main content Skip to \"About government\" We have archived this page and will not be updating it. You can use it for research or…","rawSnapshotUrl":"/api/snapshots/raw/140468","browseUrl":"https://replay.healtharchive.ca/job-1/20250418141406/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-novavax-nuvaxovid-covid-19-vaccine/summary-february-17-2022.html?wbdisable=true#ha_snapshot=140468","mimeType":"text/html","statusCode":200}